lationsbydecodingdatacomplexity.Thesepatternscouldbe biologicalvariationsorbehavioralpatterns,dependingonthe hypothesisbeingprobed.Statistical methodshavedominantly beenemployedtosupporttheexistenceorlackofsuchpatterns,whetherthesubjectofthestudyisahumanpopulation, aplantfamily,oracellculture.
However,recentevidencesuggeststhatdataaveraginghas significant limitations when dealing with heterogeneity as it masks intrapopulation diversity and homogenizes otherwise heterogeneoussubpopulations.Heterogeneityatalllevelsisa productofevolution [6] ;itconfersbetterfitnessonindividuals and thus positions populations to survive bottleneck events. Evolutionary processes produce heterogeneity at many levels from cellular (e.g., genes, chromosomes, genomes, epigenetics, and tissues) to behavioral patterns (e.g., dietary, exercise, health promotion patterns). Variations at theselevelsconstitutethebasisofnaturalselection [6, 7] .
Recentwhole-genomesequencingprojectshaveshownthe presence of millions of variations as single-nucleotide polymorphisms (SNPs), small insertions and deletions, and copy number variations (CNVs) [8] . However, the lack of proper analyticaltoolshasreducedthesignificanceofgeneticsstudies andpreventedmeaningfulinterpretationofthedata [9, 10] .
Thescientificcommunityisaddictedtostatisticalandphenetic approaches, and despite their inapplicability to certain high-throughput high-dimensional biological data, statistical parameters continue to be invoked even when their usefulness is doubtful [11] . The commonly cited reason for this is theperceivedabsenceofanalternative;butaswewilldetail inthispaper,suchalternativesindeedexist,andtheyshould be studied and employed. They are based on the fact that heterogeneity,whetherinnormalordiseaseconditions,isan evolution-basedphenomenonthathastobedealtwithbyapplyingevolutionarilycompatiblemethods.
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Heterogeneity · Parsimony · Phylogenetics · Synapomorphies · Systems biology · Clinical trial design · Complementary and alternative medicine Summary Systems biology offers cutting-edge tools for the study of complementary and alternative medicine (CAM). The advent of 'omics' techniques and the resulting avalanche of scientific data have introduced an unprecedented level of complexity and heterogeneous data to biomedical research, leading to the development of novel research approaches. Statistical averaging has its limitations and is unsuitable for the analysis of heterogeneity, as it masks diversity by homogenizing otherwise heterogeneous populations. Unfortunately, most researchers are unaware of alternative methods of analysis capable of accounting for individual variability. This paper describes a systems biology solution to data complexity through the application of parsimony phylogenetic analysis. Maximum parsimony (MP) provides a data-based modeling paradigm that will permit a priori stratification of the study cohort(s), better assessment of early diagnosis, prognosis, and treatment efficacy within each stratum, and a method that could be used to explore, identify and describe complex human patterning.
Introduction
Systemsbiologyofferssophisticatedobjectivetoolsforinvestigatinghowcomplementaryandalternativemedicine(CAM) treatmentscouldresultincomplexandindividualizedeffects onthebody [1] [2] [3] [4] [5] .Mostscientificresearchaimstoidentifythe hiddenpatternsthatexistwithinapopulationoramongpopuForschKomplementmed2012;19(suppl1) [42] [43] [44] [45] [46] [47] [48] ASystemsBiologyApproach: ParsimonyPhylogenetics 43 approachcanbeachievedfairlyreadilyinasmallnon-complex situation with one to a few variables, it becomes difficult to conduct when the contributing variables are scaled up to the tens,hundreds,orthousands [22] [23] [24] [25] [26] .
In a disease context, data heterogeneity can point out severalphenomena,suchasinter-andintra-specimendiversity in diseased specimens, a high rate of variability generation,andmultiplepathwaysofdiseasedevelopment [18, 20] . Additionally,thediseaseprocessisfurthercomplicatedbythe multiphasicanddynamicnatureofsomepathologies,suchas canceranddegenerativediseases,whichposethechallengeof whether a multiphasic and dynamic process can be modeled byabioinformaticparadigm.
Datainterpretationrequiresanalysisandsynthesiscompatible with the existing biological conceptual framework(s) and hypotheses.Thus,abiologicallycompatibleanalyticalparadigm should incorporate four elements: the high-throughput data (e.g.,genomics,metabolomics,proteomics),thediseasephenotypes(e.g.,hyperplasia,primarytumor,metastatictumor),evolutionary theory, and bioinformatics (an analytical algorithm that processes the data). Parsimony phylogenetics offers an analyticalalgorithmthatcanbringtheseelementstogetherto achievenovelmultidimensionalsystemsbiologysynthesiswithoutthetraditionaloverdependenceonstatisticalmethods.
Parsimony Phylogenetics for Analyzing and Modeling Heterogeneity
Phylogenetics,alsotermedcladistics,isananalyticalparadigm based on the principles of evolution [27] . Its current codes knownasphylogeneticsystematicswerelaiddowninthemid1950sbytheGermansystematistWilliHennig [28] .Phylogenetics differs from other systems of classifications in that, ratherthanusingoverallsimilaritytoclassifyobjects,itutilizes sharedderivedsimilarityasevidenceofrelatedness.Thepracticehasbeenappliedinmanyfieldssuchasbotany,microbiology, and zoology to construct relationships among species, populations,andindividualsinanevolutionarysense [27] .
Thegoalofaphylogeneticanalysisistomodelthedatato produce a hypothesis of relationships among the specimens under study that accurately reflects the biological processes that led to the diversity of specimens. Phylogenetics constructsthehypothesesofrelationshipsbysortingdatapoints into ancestral (normal/within the normal parameters) and derived (abnormal, above or below the selected baseline, or fallingoutsidethenormalrange)categories,andthengroupingtogetherthespecimensthatsharethesamederivedstates [28, 29] . The process of sorting out data points into derived andancestralstatesistermedpolarityassessment,datapolarization,oroutgroupcomparison.Thederivedstatesrepresent theaberrationsorthenewchanges;forexample,inadisease, theaberrationcanbeanoverexpressionofagene,up-regulationofaprotein,oramutation.
Dealing with Data of Heterogeneous Populations
Although the paradigmatic and methodological argument is broadly applicable across domains and disciplines, we will presentthecasefortheproposedapproachusingbiologicalexemplars. Heterogeneity has implications for many aspects of researchandclinicalpractice.Itnecessitatescompensatingfor individual variations that produce significant differences in rates of treatments efficacy, effectiveness and side effects as well as responses to various therapeutic modalities, including whole systems of complementary and alternative medicine (WS-CAM) [12, 13] .Forexample,inaclinicaltrialwherethe study population encompasses individuals who are poor responders to a particular treatment, the treatment's effects in goodresponderswillbeunderestimated [12] .Asinotherfields, this is an issue that is particularly important in WS-CAM research,wherepersonalizedinterventionpackagesandindividualizedtrajectoriesoftreatmentresponsearethenorm [14, 15] .
Ratherthanfocusingonthecommonalitiesofcertaingenes, metabolites,orproteins,profilingheterogeneityis bettersuited fordynamicsystems [7] .Priorto1966,naturalpopulationswere assumed to be more or less genetically uniform, even though Lewontin and Hubby [16] and Harris [17] demonstrated that polymorphisms are common throughout populations. Today, werecognizevariationatseverallevels;agene-nucleotidelevel of variation could manifest in mutations and genetic polymorphism, while a genome-chromosome level heterogeneity canbepresentasCNVs,lossofheterozygosity(LOH),andepigenetic heterogeneity such as DNA methylation, non-coding RNAs, or chromosomal folding [18] . Additionally, there are changesthattakeplaceindependentofepigeneticalterations; theseareinfluencedbyenvironmentalfactorsandareaffected bynutrition,stress,exposure,andimmuneresponses [18] .
Analyzing Heterogeneous Data for Biological Significance
Therecentclinicaltrialsoftargetedbiomedicalcancertreatmentsareexamplesofthecurrentreductionisttrendthathas produced mostly disappointing results [19] . However, the failedtargetedtreatmentapproachhasservedthepurposeof bringingtheissueofheterogeneitytotheforefrontofscientificthought [18, 20] .
Morerecently,byrecognizingtheubiquityofheterogeneity incomplexsystemsandthenegativeeffectsofignoringit,statisticians and researchers are calling for the two-stage study, wherebyinthefirststage,thestudygroupisstratifiedintowelldefined but broad populations using traditional experimental methods, followed by the construction of subgroups in the second stage [12, 21] . Similarly, CAM researchers previously identified a need for two-stage diagnosis, with the conventionalmedicinediseaseentitygroupdiagnosisfollowedbythe individualizedWS-CAMdiagnosis [4] .Althoughthetwo-stage evolution [30, 31] . Yet, it is important that any analytical methodhashighpredictivepower;itmustbeabletodifferentiate between groups of people (e.g., those that are healthy from those with disease, or those who respond to treatment fromthosewhodonot),presentthechangesthatdistinguish betweenthetwogroups,showthetransitionalspecimensthat fall in between the two states [27] , and stratify populations [32] .
We provide an example to illustrate the application of a parsimony analysis of gene expression microarray data. We selected dataset GDS1439 from the National Center of Biotechnology Information (NCBI; www.ncbi.nlm.nih.gov/sites/ entrez?db = gds), which contains 6 benign specimens, 7 primary, and 6 metastatic prostate carcinoma specimens [33] . When dealing with large datasets that contain thousands of variables, especially datasets obtained from high-throughput microarrays or mass spectrometry, there are two steps in carrying out parsimony analysis; first, polarity assessment of datapointsthroughoutgroupcomparisonintoeitherderived (abnormal in case of disease phenotypes) or ancestral (normal)mustbecarriedout.Polarityassessmenttransformsthe continuous quantitative data points of gene expressions into discreteentitiesofzeros(0s)andones(1s),wherezeroindiIn phylogenetic terminology, a shared derived state is termedsynapomorphy(apotentialbiomarker);becausesharingasynapomorphyisindicativeofarelationship,agroupof specimensthatshareoneormoresynapomorphiesiscalleda clade. Phylogenetics presents its hypotheses in a graphical tree format called the cladogram ( fig. 1 ), which is a map of clades(groupings)andtheirsupportingsynapomorphies.
There are a few methods to constructing phylogenetic cladograms (trees); among these are parsimony, maximum likelihood,andneighborjoining.Theydifferintheiralgorithmicfunctionsandthetypeofdatatheyhandle.Thesemethodshavebeencompared,andparsimonyhasturnedouttobe themostsuitableforthepurposesofdealingwithheterogeneoushigh-throughputdataofvariousdiseases.Parsimony,also knownasOccam'srazororthe'principleofsimplicity',isgenerally defined as selecting the simplest hypothesis among competingones.Inphylogeneticanalysis,itisthehypothesis that requires the least number of steps to construct, i.e., theshortesttree/cladogram,whichisusuallycalledthemost parsimonious tree. A parsimonious approach produces a multidimensional analytical tool that is data based, not specimen based, which accounts for and integrates disease heterogeneity, nature of biological data, and principles of The study group contains specimens composed of 6 benign specimens, as well as 7primaryand6metastaticprostatecarcinoma specimens [33] . The primary and metastatic specimensgroupedseparatelyfromeachother into two groups (clades); while the metastatic occupiedthetopofthecladogram,theprimary was nestled in between the metastatic and benignclades.
ForschKomplementmed2012;19(suppl1) [42] [43] [44] [45] [46] [47] [48] ASystemsBiologyApproach: ParsimonyPhylogenetics 45 cates that the value is ancestral (normal) and one indicates thatthevalueisdifferentandthereforeassumedtobederived inanevolutionarysense.So,thenewdatamatrixofpolarized bivalentvalueshasonlyzerosandones,anditisthismatrix thatwillbeprocessedinaparsimonyalgorithm.Thesecond stepistheprocessingofthepolarizedvaluesthroughamaximum parsimony algorithm to classify the specimens into a cladogram. The first step of the analysis was carrying out polarityassessmentofthegeneexpressionvaluesthatsorted the expression values into derived (abnormal) and ancestral (normal)bycomparingthevaluesofthecancerousspecimens against the range of the benign specimens for every gene in thedataset.Thenewmatrixwasprocessedwiththecomputer programMIX(theparsimonyprogramofthePHYLIPpackage)usingWagner'sparsimonymethod [34] ,whichproduced onlyonemostparsimonioustree/cladogram( fig.1) .
The cladogram of figure 1 is a graphical summary that showedthegroupings(clades),theirsynapomorphies,andatopologythatreflectstherelationshipsamongthecladesandthe directionofchangeaccumulationamongthecladesandtheir specimens. The analysis showed the primary and metastatic specimensgroupedseparatelyfromeachotherintwogroups; whilethemetastaticoccupiedthetopofthecladogram,theprimarywasnestedinbetweenthemetastaticandbenignclades. Separatingthemetastaticcasesfromtheprimaryonesonthe basisoftheirgeneexpressionisanexcellentoutcomethatconfersconfidencethatthisapproachhasgoodvalidity.Theprimaryandmetastaticcladessharedalistof302synapomorphies (uniquelysharedderivedexpressionsorpotentialbiomarkers in a biomedical sense) that separate them from the benign clades.Themetastaticspecimensatthetopendofthecladogramareseparatedfromtheprimaryspecimensbyalistof577 synapomorphiesthataresharedbytheirrespectivespecimens. Thecladogramtopologyhasdirectionality;thespecimenswith thehighestnumberofderivedstatesoccupytheupperpartof the cladogram. Therefore, one could interpret the tandem arrangementoftheprimaryandmetastaticgroupsasasequential relationship, where the initiation of the cancer required 302 derived gene expressions, while the transformation to a metastaticphenotyperequiredanadditional577changes.
Implications of Parsimony Phylogenetics
Asourexampledemonstrates,maximumparsimonyhasefficientlyandaccuratelymodeledtheheterogeneousexpression profilesofthediseasedspecimens,inthiscase,cancerwitha rapid mutation rate. The analysis precisely classified the phenotypes (or genetic patterns) based on modeling of the diseasegenotypes(geneexpressions);therewasnomixingof thethreephenotypes,andthegeneexpressiondatawereperfectlycongruentwiththeirphenotypes. Theprocessofdatapolarizationhastheaddedadvantageof reducingmeasurementvariability.Bytransformingdatapoints to distinct 1s and 0s, the comparison between specimens becomes qualitative rather than based on absolute quantitative values.Polarizationofthedataallowspoolingofmultipleexperiments,andthereforefacilitatesintra-andinter-compatibilityoftheobservedclades,typesorclasses.Inthisregard,the analysisisasystemsbiologyapproachthatcanpooldatafrom related diseases to identify the common aberrations and differentialfeaturesamongthem,e.g.,severalcancertypes [30] or WS-CAMdiagnosticsubgroups [14, 15, 17, 35] .Forexample, AlraekandBaerheim [14] subgroupedtheircystitispatientsin threegroups:(1)spleenyang/qixu,(2)kidneyyang/qixu,and (3)liverqistagnation;suchsubgroupingcanmoreobjectively be carried out by a phylogenetic analysis. Also, as Frei et al. [15] haveshown,subgroupingofpatientswithattentiondeficit hyperactivitydisorder(ADHD)beforethecommencementof atrialisimportantinordertoavoidfailure,sincepatientsvary in their response to treatment and poor responders require alternativemedication(seebelowontheuseofphylogenetics forthestratificationbeforeclinicaltrial).
From a practical aspect, a parsimony approach can be translatedintoaclinicalsettingfordiagnosis,prognosis,and post-treatmentevaluation [27] .Byconstructingacomprehensivecladogramthatincorporatesmanydiseases(forexample, a tree of cancer), the cladogram becomes an instrument for diagnosis. To diagnose a case, data can be entered into the comprehensivecladogram,thusplacingthecaseonthecladogram.Thisapproachmightalsofacilitatemoreaccurateprescriptive practices, like those used in homeopathy, in which theprocessofchoosinganindividualizedremedyortherapeutic schema often requires categorizing each patient's global homeopathicphenotype,i.e.,remedytype,bykingdom(animal,plant,ormineral)andspecificfamily [36] .
ParsimonyphylogeneticscouldalsobeappliedtoWS-CAM andintegrativetherapiesresearch.CAMclinicianshaveoften claimedthataportionofthepopulationrespondspositivelyto a particular therapy (responders) while others seem to have little to no change in outcomes (non-responders) [14, 15, 35, 37, 38] .Clinicaltriallimitations,oftencitedintheCAMliterature,havefueledacallfornewmethodologicalstrategiesand sophisticatedanalyses.Thesuccessfulanalyticaltoolistheone thatdoesnotobviateorunderplayheterogeneity-drivenvariability.Solutionssuchasgenomiccontrol,whichadjustsassociationstatisticsforeachmarkerbyauniformoverallinflation factor,compensateonlypartiallyforheterogeneity [39, 40] .
Parsimonyphylogeneticmethodscanbeusedtodifferentiateamongrespondertypesbyclassifyingintoresponder-type clades,basedonsharedsynapomorphiesorsetsofintra-population characteristics. Thus, a wider set of study participants couldbeenrolledintoCAMclinicaltrials,morecloselyaligning the trial population with those seen in clinical practice. CAMresearcherscouldbetterevaluatetreatment-effectvariabilityandtreatment-relatedrisks,whilepredictingthosepersons who are most likely to benefit from a particular CAM therapyinagivensolution [15, 41] .
Othershavesuggestedconductingmultipletrialsoftreatmentoneachindividualinan'n-of-one'-typedesigninorder to minimize the data heterogeneity. Phylogenetic analysis would allow pooling of data across these types of studies to againidentifyrespondersandnon-responders.Thus,informationgainedfromclinicaltrialscouldbemoreinformativeand moreeasilyextrapolatedtotheclinic [42] .
We propose a three-stage clinical trial model that starts withastratificationofthestudysamplebasedonphenotypic and genotypic characters. A pre-trial phase using a priori stratification by parsimony phylogenetics will delimit the subpopulations that share common biological traits (classes) ( fig. 2) . A small blood sample subjected to high-throughput analysis could provide the data needed for stratification. Becausethestratificationisdonewithoutaprioriweighingof variables,parsimonymayalsorevealthevariablesthatdefine the subpopulation partitioning. Essentially, in the first stage, the recruitment could include a wide spectrum of inclusion criteriainordertoembraceaheterogeneousstudypopulation thatwouldreflectthe'real-world'setting.Basedontheidentified clades that reveal relatedness among groups and subgroups, the second stage of the trial could be implemented knowingthatwereachedalevelofhomogeneityatbaseline withineachclade.Thus,eachcladecouldthenberandomized to either control or intervention, depending on the clinical trialtype. Amongtheindividualsofeachcladetherewillprobablybe variablelevelsofresponsivenesstotheintervention,butmost likelylessvariabilitythanbetweenclades.Thecladogramwill serve as a dynamic database for the implementation of the third stage,whichcorrespondstothetranslationoftheclinical trial findings to the clinic. This means that, prior to using a newtherapyorintervention,thepatientwillneedtosubmita bloodsampletodeterminehis/herclade.Aclademembership determines the treatment options; what dosage he/she will needorhowresponsivetotreatmentthepatientwillbe.Thus, the health care provider could make an informed decision whenrecommendingaparticulartherapyorimplementinga particulartypeoftreatment.Potentially,thiscouldleadtodecreasedtreatment-relatedrisk,improvedoutcomes,decreased costs, and treatment efficiency. Furthermore, in WS-CAM where the practitioner stratifies patients on categorical yet unifying classes (types of doshas, humors, temperaments, or imbalances in interrelationships among elements), this 
Conclusions
Using parsimony phylogenetics as a means to account for heterogeneity from the subcellular to the whole-human behavioral level of function holds extraordinary promise in expandingclinicalknowledgerelatedtoCAMtherapies,and clinical treatment in general. Using a systems biology approachandputtingdataintoanalgorithmthatcanaccurately modelsubtypesofpeople/phenomenainanevolutionarycontextoffersanovelmethodologytoclinicaldesign.Thisstands todeepenclinicianunderstandingandconfidenceformatchinginterventionstothosewhoaremostlikelytobenefit.
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method could offer a modern verification of these concepts andpotentiallyincludethemintheclinicaldesign.
The advantages of this three-stage clinical trial design could be summarized in three significant points: (i) By employing parsimonyanalysistocarryoutthepre-trialpopulationalstratificationintonaturalclades,thebaselineheterogeneity per clade will significantly be reduced; (ii) individuals' positions within a clade determine their treatment options; and(iii)byusingthecladesasadynamicdatabase,thephysiciancouldprescribethesuitabletreatmentonthebasisofthe patient'sclademembership.Ourproposedthree-stageclinical trial design encompasses the practice of personalized medicineusingasystemsbiologyapproachthataddressesmostof the currently debated issues of baseline heterogeneity, data heterogeneity,treatment-relatedrisk,andtranslationoftrials findingstotheclinic.
